Frontiers in Cardiovascular Medicine

FEBRUARY 19, 2025

Cardiovascular diseases (CVDs), characterized by a high incidence rate and high mortality, have become the leading cause of death globally. CVDs include coronary heart disease, stroke, hypertension, and peripheral vascular diseases. In China, the death rate of CVDs ranks the first in all major diseases.

Myocardial Infarction 52

Myocardial Infarction Quality of Life Heart Transplant Ischemia 52

Frontiers in Cardiovascular Medicine

JANUARY 23, 2024

Introduction Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in kidney transplant recipient (KTR). There is a dearth of standardized guidelines on optimal cardiovascular evaluation of transplant candidates. were found to have obstructive coronary artery disease (CAD).

Transplant 64

Transplant Coronary Artery Disease Myocardial Infarction Cardiovascular Disease 64

DAIC

APRIL 30, 2024

Image courtesy of Hideki Kobayashi from Shinshu University milla1cf Tue, 04/30/2024 - 12:53 April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function. However, the risk of arrhythmias following this procedure is reportedly high.

Transplant 105

Transplant Heart Transplant Myocardial Infarction Heart Attack 105

Frontiers in Cardiovascular Medicine

MAY 29, 2024

BackgroundMesenchymal stem cells (MSCs) have important research value and broad application prospects in cardiovascular diseases (CVDs). However, few bibliometric analyses on MSCs in cardiovascular diseases are available.

Cardiovascular Disease 52

Cardiovascular Disease Research Myocardial Infarction Article 52

Circulation

FEBRUARY 15, 2024

BACKGROUND:Clonal hematopoiesis of indeterminate potential (CHIP), a common age-associated phenomenon, associates with increased risk of both hematological malignancy and cardiovascular disease.

Atrial Fibrillation 45

Atrial Fibrillation Diet Myocardial Infarction Cardiovascular Disease 45

Cardiology Update

APRIL 9, 2024

EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). of patients in the PCI group compared to 3.4%

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Wellnest

DECEMBER 11, 2023

Blood Transfusions and Organ Transplants: Though rare, the virus can be transmitted through infected blood or organ donations. As beneficial as ART Therapy is, recent studies suggest that INSTIs and CCR5 antagonists exhibit cardiovascular toxicity, raising valid concerns as it can lead to a higher risk of CVDs.

Quality of Life 52

Quality of Life Myocardial Infarction Public Health Arrhythmia 52